bevacizumab + temozolomide + radiotherapy

This regimen is a **combination therapy** used primarily for the treatment of newly diagnosed or high-grade glioma, especially **glioblastoma multiforme**. It includes the following components: - **Bevacizumab**: a monoclonal antibody that targets vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis in tumors. - **Temozolomide**: an oral alkylating agent that modifies DNA, leading to cell cycle arrest and apoptosis, particularly in rapidly dividing tumor cells. - **Radiotherapy**: external beam radiation that damages tumor cell DNA and promotes cell death. **Mechanism of action**: Bevacizumab acts as an anti-angiogenic agent by inhibiting VEGF, restricting tumor vascularization and growth. Temozolomide introduces methyl groups into DNA at the O6 and N7 positions of guanine, resulting in cytotoxicity and apoptosis in tumor cells. Radiotherapy induces DNA double-strand breaks, amplifying cytotoxicity via direct DNA damage and by generating reactive oxygen species. **Regimen details**: - Bevacizumab and temozolomide are administered concurrently with radiotherapy during the initial phase, followed by bevacizumab and temozolomide alone in maintenance therapy[1][2]. - Used for the initial and adjuvant treatment phases, particularly in glioblastoma. - This combination aims to improve progression-free survival and may offer modest overall survival benefits when compared to standard therapies, though with an increased risk of adverse events such as fatigue, thrombocytopenia, and risk of CNS hemorrhage[2].

Other names

bevacizumab and temozolomide plus radiationbevacizumab + temozolomide + radiationbevacizumab + temozolomide + RTbevacizumab+TMZ+radiotherapy